Shares of Progyny, Inc. (NASDAQ:PGNY - Get Free Report) have received an average rating of "Hold" from the twelve analysts that are presently covering the company, MarketBeat.com reports. Seven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $27.73.
A number of research firms have recently weighed in on PGNY. JPMorgan Chase & Co. reduced their price target on shares of Progyny from $31.00 to $22.00 and set an "overweight" rating on the stock in a research note on Thursday, September 19th. Leerink Partnrs cut shares of Progyny from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 7th. Leerink Partners dropped their price target on Progyny from $25.00 to $21.00 and set a "market perform" rating for the company in a research note on Thursday, September 19th. Jefferies Financial Group reduced their price objective on Progyny from $31.00 to $24.00 and set a "buy" rating on the stock in a research report on Thursday, September 19th. Finally, BTIG Research lowered Progyny from a "buy" rating to a "neutral" rating in a research note on Wednesday, August 7th.
Check Out Our Latest Stock Report on Progyny
Shares of NASDAQ:PGNY opened at $16.65 on Thursday. Progyny has a 1 year low of $13.93 and a 1 year high of $42.08. The stock has a market capitalization of $1.50 billion, a price-to-earnings ratio of 27.30, a price-to-earnings-growth ratio of 1.62 and a beta of 1.45. The company's 50 day simple moving average is $23.33 and its 200 day simple moving average is $28.24.
Progyny (NASDAQ:PGNY - Get Free Report) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $0.17 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.17. Progyny had a return on equity of 11.97% and a net margin of 5.54%. The company had revenue of $304.09 million for the quarter, compared to analyst estimates of $305.32 million. During the same quarter last year, the company posted $0.15 EPS. The company's revenue for the quarter was up 8.8% compared to the same quarter last year. As a group, analysts anticipate that Progyny will post 0.64 EPS for the current fiscal year.
In other Progyny news, President Michael E. Sturmer sold 9,030 shares of the firm's stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $30.00, for a total value of $270,900.00. Following the completion of the sale, the president now directly owns 362,583 shares in the company, valued at $10,877,490. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Cheryl Scott sold 1,462 shares of the stock in a transaction on Friday, June 28th. The stock was sold at an average price of $28.39, for a total value of $41,506.18. Following the transaction, the director now directly owns 10,098 shares in the company, valued at approximately $286,682.22. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, President Michael E. Sturmer sold 9,030 shares of the business's stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $30.00, for a total transaction of $270,900.00. Following the sale, the president now owns 362,583 shares of the company's stock, valued at approximately $10,877,490. The disclosure for this sale can be found here. Company insiders own 12.30% of the company's stock.
A number of large investors have recently made changes to their positions in the business. Farallon Capital Management LLC raised its holdings in shares of Progyny by 120.8% in the 2nd quarter. Farallon Capital Management LLC now owns 1,308,500 shares of the company's stock worth $37,436,000 after acquiring an additional 715,900 shares during the last quarter. Wellington Management Group LLP purchased a new stake in shares of Progyny in the fourth quarter worth approximately $14,608,000. Norges Bank bought a new position in shares of Progyny in the fourth quarter valued at approximately $14,198,000. Eagle Asset Management Inc. grew its holdings in Progyny by 102.7% during the fourth quarter. Eagle Asset Management Inc. now owns 649,897 shares of the company's stock worth $24,163,000 after buying an additional 329,288 shares in the last quarter. Finally, Redmile Group LLC purchased a new stake in Progyny in the 1st quarter valued at $12,241,000. 94.93% of the stock is owned by institutional investors.
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Progyny, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Progyny wasn't on the list.
While Progyny currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.